β-Adrenergic Inhibition Prevents Action Potential and Calcium Handling Changes during Regional Myocardial Ischemia

Shannon R Murphy1, Lianguo Wang1, Zhen Wang1

  • 1Department of Pharmacology, University of California, DavisDavis, CA, United States.

Frontiers in Physiology
|September 13, 2017
PubMed

Insights

Beta-adrenergic receptor (β-AR) blockers prevent action potential duration shortening and abnormal calcium handling during myocardial infarction ischemia. This study reveals direct electrophysiological benefits of β-AR inhibition independent of heart rate or contractility.

Area of Science:

  • Cardiovascular Physiology
  • Cardiac Electrophysiology
  • Myocardial Ischemia Research

Background:

  • Beta-adrenergic receptor (β-AR) blockers are used in acute myocardial infarction (MI) to reduce cardiac workload.
  • Direct effects of β-AR blockers on ventricular electrophysiology and intracellular calcium handling during ischemia are not well understood.

Purpose of the Study:

  • To investigate the direct impact of β-AR inhibition on ventricular electrophysiology and sarcoplasmic reticulum (SR) Ca2+ handling during regional ischemia.
  • To determine if β-AR blockers offer benefits independent of their chronotropic and inotropic effects.

Main Methods:

  • Isolated rabbit hearts subjected to 15 minutes of regional ischemia.
  • Optical mapping of transmembrane potential and SR Ca2+ dynamics.
  • Hearts were paced and contraction inhibited to control for heart rate and contractility.
  • Comparison between untreated ischemic hearts and those pre-treated with propranolol.

Main Results:

  • Propranolol prevented the shortening of action potential duration (APD80) in the ischemic zone.
  • β-AR inhibition normalized SR Ca2+ reuptake and prevented SR Ca2+ alternans.
  • Propranolol pre-treatment enhanced SR Ca2+ release amplitude in the ischemic zone.

Conclusions:

  • β-AR inhibition exerts direct favorable effects on ventricular electrophysiology and Ca2+ handling during acute ischemia.
  • These benefits are independent of the drug's effects on heart rate and contractility.
  • β-AR blockers may offer protective mechanisms beyond reducing cardiac workload in MI.

Related Concept Videos

Antihypertensive Drugs: Action of Calcium Channel Blockers01:18

Antihypertensive Drugs: Action of Calcium Channel Blockers

Calcium ions are essential to contract smooth muscle cells in blood vessels. They enter these cells through voltage-dependent calcium channels, specifically L-type calcium channels in the cell membrane. These L-type calcium channels are integral to the excitation-contraction coupling process in smooth muscle. When a stimulus is received by smooth muscle cells, their membrane depolarizes. This alteration in membrane potential instigates the opening of L-type calcium channels. As a result,...
1.9K
Adrenergic Receptors: β Subtype01:26

Adrenergic Receptors: β Subtype

β-adrenoceptors have varied sensitivities towards adrenaline, noradrenaline, and isoprenaline. The order of agonist potency is as follows:
Isoprenaline > Adrenaline > Noradrenaline
Neurotransmitter binding to these receptors causes activation of adenylyl cyclase resulting in increased concentrations of cAMP and modulation of calcium ion channels within the cell. They are further classified into β1, β2, and β3 subtypes.
β1-adrenoceptors: β1-adrenoceptors...
4.0K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
1.3K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.8K
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
2.1K
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.6K